Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$118.13 USD

118.13
4,982,512

+0.50 (0.43%)

Updated Sep 17, 2024 04:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Gains CE Mark for Quantitative Serology Testing

by Zacks Equity Research

The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.

Abbott (ABT) Stock Moves -0.23%: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $106.79 in the latest trading session, marking a -0.23% move from the prior day.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.

Abbott (ABT) Launches Immunity Boosting Hydration Solution

by Zacks Equity Research

Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.

Sriparna Ghosal headshot

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

by Sriparna Ghosal

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Abbott (ABT) Stock Moves -0.45%: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $106.32, moving -0.45% from the previous trading session.

Trina Mukherjee headshot

4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

by Trina Mukherjee

Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

Abbott's (ABT) Libre 2 Cleared in Canada, Boosts CGM Prospects

by Zacks Equity Research

Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $107.53, marking a -0.57% move from the previous day.

Debanjana Dey headshot

4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success

by Debanjana Dey

Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.

Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus

by Zacks Equity Research

Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic

The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI

Sheraz Mian headshot

Top Stock Reports for NVIDIA, Pfizer & Abbott

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Pfizer (PFE) and Abbott Laboratories (ABT).

Why Is Abbott (ABT) Up 1.4% Since Last Earnings Report?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.

by Zacks Equity Research

Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.

Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical

by Zacks Equity Research

Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

by Trina Mukherjee

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Trina Mukherjee headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

by Trina Mukherjee

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.

Sheraz Mian headshot

Top Stock Reports for Microsoft, Tesla & AT&T

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Tesla (TSLA) and AT&T (T).

Surging Earnings Estimates Signal Upside for Abbott (ABT) Stock

by Zacks Equity Research

Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark

by Zacks Equity Research

BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.

    OPKO Health's (OPK) BioReference Laboratories Unveils New Test

    by Zacks Equity Research

    OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.

      Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

      by Zacks Equity Research

      In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.

      Mark Vickery headshot

      Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell

      by Mark Vickery

      Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.

      Earnings Data Deluge

      by Zacks Equity Research

      Earnings Data Deluge